<DOC>
	<DOCNO>NCT00679926</DOCNO>
	<brief_summary>Once daily antiretroviral therapy Viread ( tenofovir DF , 300mg ) plus Kaletra ( LPV/r , 800mg/200mg ) effective suppress maintain suppression HIV RNA &lt; 50 copies/ml antiretroviral naïve patient 48 week therapy .</brief_summary>
	<brief_title>Kaletra Viread Antiretroviral Naïve Patients</brief_title>
	<detailed_description>This study phase IV prospective , open-label , control treatment protocol consist daily Kaletra dose 800mg lopinavir 200mg ritonavir four combination tablet plus Viread dose 300 mg tenofovir DF . This single site , multi-investigator , study 48 week . Consecutive eligible patient enrol study reach enrollment goal 30 patient . Eligible patient identify screened routine initial follow-up visit Internal Medicine Specialty Services Clinic . This clinic serf HIV/AIDS specialty care clinic subdivision Department Internal Medicine , Oklahoma State University Center Health Sciences College Osteopathic Medicine . The study site currently serve &gt; 700 person live HIV northeast Oklahoma four five antiretroviral naïve patient see week . Patients meet inclusion criterion receive routine standard care program prescribe DHHS guideline . Patients Complete Blood Count ( CBC ) , Complete Metabolic Profile ( CMP ) , fast lipid profile , CD4 count , HIV-1 RNA level , prescribe indicated laboratory preform baseline throughout study describe Visits Evaluations section protocol . All aforementioned laboratory test perform Diagnostic Laboratories Oklahoma , division Quest Diagnostics . Any antiretroviral resistance test perform Virologic Labs , Inc. Adherence assess discontinuation study indicate evaluation virologic failure Memory Electronic Monitoring Systems cap pharmacy refill data . Patients monitor study visit tolerability adverse event . Patients develop study relate Grade 1 2 Adverse Events ( Aes ) may continue study . Those develop Grade 3 4 AEs study medication discontinue . Patients asymptomatic elevation triglyceride Low Density Lipoprotein ( LDL ) cholesterol level may treat appropriate lipid lower therapy investigator discretion .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year age document HIV1 infection 2 . Naïve antiretroviral therapy 3 . Able willing provide write informed consent 4 . No CD4 restriction 5 . HIV1 RNA level &gt; 5000 c/mL 6 . Female patient must meet additional criterion 1 . Nonchildbearing potential 2 . Negative serum pregnancy test screen 3 . Willingness abstain sexual intercourse use double barrier contraception 1 . Presence follow : 1 . Aminotransferases &gt; 3xULN 2 . Hemoglobin concentration &lt; 8.0g/dl 3 . Absolute neutrophil count &lt; 800 cells/cubic mm 4 . Platelet count &lt; 50,000 cells/cubic mm 5 . Acute illness , acute illness ≤7 day 6 . Presence Opportunistic Infection , OI within 30 day screen 7 . Acute chronic active Hepatitis B 8 . Hepatitis C 9 . Creatinine Clearance &lt; 50 mL/min 2 . Pregnant breastfeed woman 3 . Presence illness , physical behavioral condition ( i.e. , substance abuse , exclude cannabis ) impair patient 's ability participate 4 . Patient , opinion investigator , unlikely complete study protocol adhere study drug regimens 5 . Concurrent use medication may potentially interact study medication include : astemizole , terfenadine , rifampin , dihydroergotamine , ergonovine , ergotamine , methylergonovine , cisapride , St. John 's wort , lovastatin , simvastatin , pimozide , midazolam , triazolam , adefovir , cidofovir , acyclovir , ganciclovir , valganciclovir . 6 . Patient suffers serious medical condition may opinion investigator compromise safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV/AIDS</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>